Physician Views snap poll: Asking dermatologists to assess Pfizer's new Phase III atopic dermatitis data for abrocitinib

Pfizer announced impressive looking efficacy data for its once-daily oral JAK inhibitor abrocitinib for the treatment of moderate-to-severe atopic dermatitis. This will raise hopes within the company that abrocitinib can potentially compete with Sanofi and Regeneron Pharmaceuticals' injectable therapy Dupixent.

Analysis - ViewPoints: Pfizer's abrocitinib raises bar for JAKs in atopic dermatitis

With new data gleaned from a 12-week study, more results are needed to full establish abrocitinib's safety profile, though Pfizer did note that no pulmonary embolism, DVT, MACE or malignancy (the main safety concerns associated with the JAK inhibitor class) were seen in the JADE MONO-1 trial. Results from JADE MONO-2 - already top-lined as being positive - are due to be shared by Pfizer in early 2020.

In the meantime, we are sharing these new data for abrocitinib with dermatologists based in the US and EU3 (France, Germany and the UK) to gauge their initial response to the study results. Results from this snap-poll should be published later this week for FirstWord Pharma PLUS subscribers.

______________

Q. Do you routinely treat moderate-to-severe atopic dermatitis?

Yes

No

_____________

Q. The Phase III JADE MONO-1 study investigated the JAK inhibitor abrocitinib as an oral, once-daily treatment for moderate-to-severe atopic dermatitis. It randomised 387 subjects to receive abrocitinib at one of two doses or placebo for 12 weeks. The study's first co-primary endpoint was the proportion of patients who achieved an Investigator Global Assessment (IGA) score of clear or almost clear skin and two-point or greater improvement relative to baseline, while the second main goal was the proportion of patients who achieved at least a 75% or greater change from baseline in their Eczema Area and Severity Index (EASI) score.

Results show that the IGA response rate was 43.8% in patients given the higher dose of abrocitinib and 23.7% in the lower-dose group, versus 7.9% for placebo. Response rates for EASI-75 were 62.7% and 39.7% in patients who received the higher and lower doses of abrocitinib, respectively, versus 11.8% for placebo.

The most frequently reported adverse events in abrocitinib-treated patients (200mg, 100mg) were short-lasting nausea (20.1%, 9%), headache (9.7%, 7.7%) and nasopharyngitis (11.7%, 14.7%). The rate of serious adverse events was 3.2% for both doses of abrocitinib (1.9% for placebo) and 5.8% of patients of abrocitinib patients (both doses) discontinued treatment due to serious adverse events.

How would you rate the clinical innovation of this product versus current standard-of-care therapy?

1 - None

2

3

4 - Moderate

5

6

7 - Very high

_____________

Q. How would you rate this product as meeting an unmet clinical need?

1 - None

2

3

4 - Moderate

5

6

7 - Very high

_____________

Q. How would you rate your likelihood of using this product if approved on the strength of available clinical data?

1 - None

2

3

4 - Moderate

5

6

7 - Very high

_____________

Q. Assuming real-world use confirms the clinical profile of this drug (as per its clinical study data), how frequently would you expect to use versus current standard-of-care therapy?

1 - None

2

3

4 - Moderately

5

6

7 - Very frequently

______________

Results and related analysis will shortly be published for FirstWord Pharma PLUS subscribers to read, with the opportunity for non-FirstWord Pharma PLUS subscribers to purchase these findings. To be notified when poll results and analysis become available, please click here.

As always, FirstWord would very much like to receive your feedback and suggestions.

Note: FirstWord Physician Views are a fast-turnaround service to conduct instant polls of up to five questions with guaranteed samples that include physicians from dozens of specialties in major markets. To conduct this poll with a different audience, or an entirely different poll, contact us at info@firstwordpharma.com.

Disclaimer: FirstWord follows market research best practices in conducting its Physician Views polls.  However, Physician Views results should be considered directional and clients should use their market research resources for statistical analysis and conclusions required with very high confidence levels.

To read more Physician Views articles, click here.